Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease

Brain

Volumn 119, Issue 6, 1996, Pages 2097-2103

  Morrish, P K ^a   Sawle, G V ^b   Brooks, D J ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Intrastriatal; Parkinson's disease; Progression; 18F dopa

Indexed keywords

DEOXYGLUCOSE; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; FLUORODEOXYGLUCOSE F 18; DOPAMINE;

ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; METABOLISM; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; SCINTISCANNING; ADULT; AGED; BASAL GANGLION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DISEASE SEVERITY; DOPAMINE METABOLISM; ISOTOPE LABELING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

DEOXYGLUCOSE; DIHYDROXYPHENYLALANINE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030463280     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/119.6.2097     Document Type: Article

References (32)

1. Bloomfleld PM, Sawle GV, Frackowiak RSJ. A method for intersubject comparison of 18F-6-L-fluorodopa positron emission tomography studies. J Cereb Blood Flow Metab 1991; 11 Suppl 2 S609.
2. Boyes BE, Cumming P, Martin WRW, McGeer EG. Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. Life Sci 1986; 39: 2243-52.
3. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 1990a; 113: 1539-52.
4. Brooks DJ, Ibañez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy [see comments]. Ann Neurol 1990b; 28: 547-55. Comment in: Ann Neurol 1991; 29: 689-90.
5. Brooks DJ, Ibañez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy [see comments]. Ann Neurol 1990b; 28: 547-55. Comment in: Ann Neurol 1991; 29: 689-90.
6. Burn DJ, Mark MH, Playford ED, Maraganore DM, Zimmerman TR Jr, Duvoisin RC, et al. Parkinson's disease in twins studied with 18-Fdopa and positron emission tomography. Neurology 1992; 42: 1894-900.
7. Calne DB, Langsten JW, Martin WRW, Stoessl AJ,Ruth TJ, Adam MJ, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985; 317: 246-8.
8. Di Rocco A, Molinari SP, Kollmeier B, Yahr MD. Parkinson's disease: progression and mortality in the L-dopa era. Adv Neurol 1996; 69: 3-11.
9. Eidelberg D, Takikawa S, Dhawan D, Chaly T, Robeson W, Dahl R, et al. Striatal 18F-dopa uptake: absence of an aging effect [see comments]. J Cereb Blood Flow Metab 1993; 13: 881-8. Comment in: J Cereb Blood Flow Metab 1994; 14: 882-3.
10. Eidelberg D, Takikawa S, Dhawan D, Chaly T, Robeson W, Dahl R, et al. Striatal 18F-dopa uptake: absence of an aging effect [see comments]. J Cereb Blood Flow Metab 1993; 13: 881-8. Comment in: J Cereb Blood Flow Metab 1994; 14: 882-3.
11. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park (NJ): MacMillan Healthcare Information, 1987: 153-63.
12. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-301.
13. Flaherty AW, Graybiel AM. Anatomy of the basal ganglia. In: Marsden CD, Fahn S, editors. Movement disorders 3. Oxford: Butterworth-Heinemann, 1994: 3-27.
14. Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, et al. Bilateral fetal nigral transplantation into the postcommissural putamen Parkinson's disease: six month follow-up. Ann Neurol 1995; 38: 379-88.
15. Genstat 5 Committee of the Statistics Department Rothamsted Experimental Station, Genstat. Genstat 5 Release 3 Reference Manual. Oxford: Oxford University Press, 1993.
16. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. [Review], J Neurol Neurosurg Psychiatry 1988; 51: 745-52.
17. Holthoff VA, Vieregge P, Kessler J, Pietrzyk U, Herholz K, Bonner J, et al. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol 1994; 36: 176-82.
18. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988; 318: 876-80.
19. Kish SJ, Zhong XH, Hornykiewicz O, Haycock JW. Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? Ann Neurol 1995; 38: 260-4.
20. Lindvall O, Widner H, Rehncrona S, Brundin P, Odin P, Gustavii B, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 1992; 31: 155-65.
21. 18F]dopa PET studies and its application to longitudinal studies of Parkinson's disease. J.Cereb Blood Flow Metab 1995; 15 Suppl 1: S751.
22. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119:585-91.
23. Pate BD, Kawamata T, Yamada T, McGeer EG, Hewitt KA, Snow BJ, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993; 34: 331-8.
24. Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin JF, et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 1995; 38: 580-8.
25. Robb RA, Hanson DP. A software system for interactive and quantitative visualization of multidimensional biomedical images. Australas Phys Eng Sci Med 1991; 14: 9-30.
26. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RSJ. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 1990; 28: 799-804.
27. Sawle GV, Playford ED, Burn DJ, Cunningham VJ, Brooks DJ. Separating Parkinson's disease from normality: discriminant function analysis of fluorodopa F18 positron emission tomography data. Arch Neurol 1994; 51: 237-43.
28. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 1989; 26: 551-7.
29. Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993; 34: 324-30.
30. Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl D, Zanzi I,et al. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med 1994; 35: 955-63.
31. Vingerhoets FJG, Schulzer M, Ruth TJ, Holden JE, Snow BJ. Reproducibility and discriminating ability of Fluorine-18-6-fluoro-L-dopa PET in Parkinson's disease. J Nucl Med 1996; 37: 421-6.
32. Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 1992; 16: 620-33.